Notably, CDK6 interference or treatment with the small molecule CDK6 inhibitor palbociclib effectively counteracted the pro-proliferative effect induced by IGF2BP3 while sensitizing bladder cancer cells to cisplatin. The gene discussed is IGF2BP3; the disease is urinary bladder carcinoma.